tasquinimod   Click here for help

GtoPdb Ligand ID: 8098

Synonyms: ABR-215050
Compound class: Synthetic organic
Comment: Tasquinimod is an orally active allosteric inhibitor of HDAC4 [1]. It has antiangiogenic effects.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 71.77
Molecular weight 406.11
XLogP 4.85
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cccc2c1c(O)c(C(=O)N(c1ccc(cc1)C(F)(F)F)C)c(=O)n2C
Isomeric SMILES COc1cccc2c1c(O)c(C(=O)N(c1ccc(cc1)C(F)(F)F)C)c(=O)n2C
InChI InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
InChI Key ONDYALNGTUAJDX-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Tasquinimod is being assessed in Phase 2I clinical trials as an antineoplastic in patients with metastatic castrate resistant prostate cancer (see NCT01234311 and NCT02057666). A Phase 2 study is underway for hepatocellular, ovarian, renal cell and gastric cancers (NCT01743469).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tasquinimod is reported to bind to the regulatory Zn2+ binding domain of HDAC4 [1], preventing it from complexing with N-CoR (nuclear receptor co-repressor 1) and HDAC3, which in turn reduces histone deacetylation and subsequent transcription factor binding (such as hypoxia inducible factor 1α) and gene transcription. This effect prevents the epigenetic reprogramming of cells within the tumour microenvironment which is essential for their continued growth and survival in this increasingly hostile space. Neo-angiogenesis is thereby inhibited and the tumour cells die.